BSE: GLAXO - GlaxoSmithKline Pharmaceuticals Limited

半年間の収益性: -20.42%

プロモーションスケジュール GlaxoSmithKline Pharmaceuticals Limited


会社について

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally.

さらに詳しく
The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

ISIN INE159A01016
Industry Pharmaceuticals
Sector Health Care
Валюта inr
Валюта отчета inr
Див.доход ао 1.17
Дивиденд ао 44
Сайт https://india-pharma.gsk.com
1日あたりの価格変動: -0.5741% (2090.2)
週ごとの価格変動: -6.81% (2230.1)
月ごとの料金変更: -7.82% (2254.45)
3ヶ月間の価格変動: -23.29% (2709.15)
半年間の価格変動: -20.42% (2611.55)
年間の価格変動: -7.96% (2257.95)
3年間の価格推移: +20.52% (1724.3)
5年間の価格推移: +24.59% (1668)
10年間の価格推移: 0% (2078.2)
年初からの価格変動: -5.04% (2188.45)

過小評価

名前 意味 学年
P/S 9.66 1
P/BV 18.71 1
P/E 56.38 2
EV/EBITDA 24.13 5
合計: 4.5

効率

名前 意味 学年
ROA, % 17.14 5
ROE, % 33.53 9
合計: 4.5

配当金

名前 意味 学年
Div yield, % 1.8 4.5
DSI 0.8571 8.57
合計: 3.95

義務

名前 意味 学年
Debt/EBITDA 0.0172 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % 6.74 1
収益性 Ebitda, % 23.53 4
収益性 EPS, % 11.29 2
合計: 5

スーパーバイザー 役職 支払い 生年
Mr. Bhushan Akshikar MD & Executive Director 32.37M
Mr. Juby Chandy Whole-Time Director & CFO 54.12M 1977 (48 年)
Mr. Amit G. Pandey Executive Vice President of Legal N/A
Ms. Simrat Sohal Vice President of Ethics & Compliance N/A
Mr. Chinmay Sharma Executive Vice President of Human Resources N/A
Ms. Sukanya Choudhary Executive Vice-President of Regulatory Affairs N/A
Ms. Aparajita Rajput Vice President of Technology
Mr. Ajay Avinash Nadkarni VP of Administration & Real Estate and Company Secretary
Mr. Ransom D'Souza Executive Vice President of Communications & Government Affairs
Mr. Shourov Mukherjee Executive Vice-President of Adult Vaccines

住所: India, Mumbai, GSK House - Googleマップで開く, Yandexマップを開く
Webサイト: https://india-pharma.gsk.com